

## ONTOGENY OF CYTOSOLIC PHOSPHOLIPASE A<sub>2</sub> ACTIVITY IN RAT BRAIN

Yoshihiro Yoshihara, Mie Yamaji, Miwa Kawasaki  
and Yasuyoshi Watanabe\*

Department of Neuroscience, Osaka Bioscience Institute,  
6-2-4, Furuedai, Suita-shi, Osaka 565, Japan

Received April 14, 1992

---

**SUMMARY:** We investigated developmental changes in the activity of cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) in the rat brain. When the cytosolic fractions from rat brain of various ages were examined by gel filtration chromatography, cPLA<sub>2</sub> activity was detected at about 100 kDa in all developmental stages. However, the magnitude of cPLA<sub>2</sub> activity differed significantly. The cPLA<sub>2</sub> activity was highest in the brain of day-12 embryo, gradually decreased toward birth, and retained a constant level into adulthood. This result suggests that cPLA<sub>2</sub> plays an important role in the early development of the nervous system. © 1992 Academic Press, Inc.

---

Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) is a rate-limiting enzyme in the arachidonic acid cascade in a variety of cells and tissues including brain (1). The arachidonic acid released is subsequently converted to eicosanoids such as prostaglandins, thromboxanes and leukotrienes (2). These eicosanoids act as neuroregulators in various physiological and pathological events occurring in the central nervous system (3-6).

We previously reported the presence of a novel type of PLA<sub>2</sub> (cPLA<sub>2</sub>) in rat brain, a cytosolic 100-kD enzyme, which is activated by micromolar concentrations of Ca<sup>2+</sup>, and translocates from cytosol to membrane in a Ca<sup>2+</sup>-dependent manner (7). Recently, Clark *et al.* (8) and Sharp *et al.* (9) independently cloned and sequenced a cDNA encoding the high molecular weight cytosolic PLA<sub>2</sub> from a U937 human monocyte cell line cDNA library.

---

\* To whom correspondence should be addressed.

The abbreviations used are: cPLA<sub>2</sub>, cytosolic phospholipase A<sub>2</sub>; EGTA, ethylene glycol bis(β-aminoethylether)-N,N',N'-tetraacetic acid.

Based on several properties such as  $\text{Ca}^{2+}$ -sensitivity, molecular weight and  $\text{Ca}^{2+}$ -induced translocation, cPLA<sub>2</sub> in rat brain cytosol appears to be identical with that in U937 cells. In the present study, we have investigated the changes in cPLA<sub>2</sub> activity during development of the central nervous system of the rat.

## MATERIALS AND METHODS

**Materials:** L- $\alpha$ -1-stearoyl-2-(1-<sup>14</sup>C)arachidonoyl phosphatidylcholine (1.85 GBq/mmol) was purchased from Amersham. Superose 6 HR 10/30 column was from Pharmacia; and Centriprep, from Amicon. All other chemicals were of reagent grade from Nacalai Tesque.


**Partial Purification of cPLA<sub>2</sub> from Rat Brain:** Brains from male Wistar rats of various ages (from embryonic day 12 to postnatal day 80) were homogenized in 10 vol. of 10 mM Tris-HCl (pH 7.4) containing 1 mM EGTA (buffer A), and centrifuged at 100,000 x g for 60 min. The supernatant was concentrated to 0.5 ml with a Centriprep 10 device and applied to a Superose 6 HR 10/30 column equilibrated with buffer A containing 100 mM NaCl. An aliquot of each fraction was assayed for PLA<sub>2</sub> activity.

**Assay of PLA<sub>2</sub> Activity:** PLA<sub>2</sub> activity was measured essentially according to Teramoto *et al.* (10). The standard incubation mixture (100  $\mu$ l) contained 100 mM Tris-HCl (pH 8.3), 4 mM  $\text{CaCl}_2$ , 50 % glycerol and 500 pmol of L- $\alpha$ -1-stearoyl-2-(1-<sup>14</sup>C)arachidonoyl phosphatidylcholine. The reaction was carried out at 37°C for 30 min and stopped by the addition of 400  $\mu$ l of Dole's reagent. The fatty acid released was extracted and its radioactivity was counted in liquid scintillation counter.

## RESULTS AND DISCUSSION


In a previous paper (7), we demonstrated the existence of two types of PLA<sub>2</sub> in rat brain cytosol. One is the higher molecular weight PLA<sub>2</sub> (PLA<sub>2</sub>-H) which appeared as a broad peak of 200 - 500 kDa and whose activity was partially inhibited by the addition of  $\text{Ca}^{2+}$ . The other is a 100 kDa-PLA<sub>2</sub> (cPLA<sub>2</sub> or PLA<sub>2</sub>-L) that is activated by  $\text{Ca}^{2+}$  at  $\mu$ M concentrations and translocates from cytosol to membrane. In the present study, 50 % glycerol was included in the assay medium, because the latter cPLA<sub>2</sub> activity was greatly enhanced by 50 % glycerol (Fig. 1A). On the other hand, the activity of PLA<sub>2</sub>-H was strongly inhibited by 50 % glycerol (Fig. 1B).

Fig. 2 shows typical elution profiles of rat brain cytosol of embryonic day 15 (A) and postnatal day 80 (B) from a Superose 6 HR 10/30 gel filtration column. In both cases, cPLA<sub>2</sub> activity appeared as a single peak at about 100 kDa, and absolutely required  $\text{Ca}^{2+}$  for the activity (data not shown). However, the



**Fig. 1.** Effect of Glycerol on cPLA<sub>2</sub> (PLA<sub>2</sub>-L) and PLA<sub>2</sub>-H Activities.

cPLA<sub>2</sub> and PLA<sub>2</sub>-H were partially purified from rat brain cytosol by gel filtration chromatography according to Yoshihara and Watanabe (7), and assayed for PLA<sub>2</sub> activity with various concentrations of glycerol. PLA<sub>2</sub> activity is represented as % of control (without glycerol). Specific activities of cPLA<sub>2</sub> and PLA<sub>2</sub>-H without glycerol were 2.26 and 0.74 nmol arachidonic acid liberated /30 min/ mg protein at pH 8.3, respectively.




**Fig. 2.** Typical Elution Profiles of cPLA<sub>2</sub> Activity obtained by Superose 6 HR 10/30 Column Chromatography.

Concentrated cytosol (0.5 ml) from rat brain of embryonic day 15 (A) or postnatal day 80 (B) was loaded onto a gel filtration column equilibrated with buffer A containing 100 mM NaCl. Flow rate was 0.4 ml/min, and 0.4 ml fractions were collected. An aliquot (28  $\mu$ l) of each fraction was assayed for PLA<sub>2</sub> activity (hatched column). Dashed lines indicate the absorbance at 280 nm.

magnitude of cPLA<sub>2</sub> activity significantly differed between embryonic (A) and adult (B) brain.

Detailed changes in cPLA<sub>2</sub> activity in rat brain during development were next investigated. Samples of brain cytosol from embryonic day 12, 15, 19, and postnatal day 3, 35, 80 were subjected to gel filtration chromatography, and cPLA<sub>2</sub> activity at each age was measured. Elution profiles of cPLA<sub>2</sub> activity from various specimens were similar to those in Fig. 2. As shown in Fig. 3, the highest activity was detected at embryonic day 12. A gradual decrease in activity was observed toward birth, and no significant change was seen after postnatal day 35. The cPLA<sub>2</sub> activity of the embryonic day-12 brain was 5.5-fold higher than that of the adult brain.

The development of the nervous system includes a variety of events such as neuronal differentiation and migration, neuronal cell death, process outgrowth and guidance, synapse formation, gliogenesis and myelination (11). In particular, the first axonal outgrowth and guidance begin at the middle of embryonic development in mammals (12). cPLA<sub>2</sub> may be involved in such developmental events in the embryonic nervous system. Negre-Aminou *et al.* (13) demonstrated that growth cone preparations isolated from embryonic rat brain exhibit elevated levels of free arachidonic acid and that the rate of arachidonic acid turnover is very high in isolated growth cones. These facts may be attributed to the high activity of cPLA<sub>2</sub> in embryonic brain. Therefore,



**Fig. 3.** Developmental Changes in cPLA<sub>2</sub> Activity in Rat Brain.

cPLA<sub>2</sub> activities in rat brain cytosol of embryonic day 12, 15, 19, postnatal day 3, 35, and 80 were measured after partial purification with a Suprose 6 HR 10/30 column as described in Materials and Methods. Values are expressed as mean  $\pm$  SEM (n=4 for embryonic day 12, 15, 19, postnatal day 3 and 35; n=7 for postnatal day 80).

cPLA<sub>2</sub> might be a part of biochemical machinery that regulates the growth cone motility resulting in axonal guidance.

Though we do not know at present the reason for the higher activity of cPLA<sub>2</sub> in embryonic brain, several explanations are plausible. (A) The cPLA<sub>2</sub> enzyme itself in the embryonic brain is in greater concentration than in the adult brain. (B) Some unidentified activator of cPLA<sub>2</sub> is present in the embryonic brain, or some unidentified inhibitor is present in the adult brain. (C) cPLA<sub>2</sub> undergoes some structural change or modification during neural development, such as phosphorylation, dephosphorylation, limited proteolysis, etc. Preliminarily, RT/PCR (reverse transcription/polymerase chain reaction) analysis with cPLA<sub>2</sub>-specific oligonucleotide primers and Western blot analysis with anti-cPLA<sub>2</sub> peptide antibody revealed that there seems to be no difference in the amount of cPLA<sub>2</sub> transcript and protein between embryonic and adult brain, thus eliminating possibility "A" above mentioned. Studies are now in progress to elucidate the mechanism and physiological meaning of this ontogenic change in cPLA<sub>2</sub> activity.

**ACKNOWLEDGMENTS:** The authors are grateful to Prof. Keizo Inoue and Dr. Ichiro Kudo (Department of Health Chemistry, Faculty of Pharmaceutical Sciences, the University of Tokyo) for useful discussions, and to Dr. Larry D. Frye for critical reading of the manuscript. This work was supported in part by the Special Coordination Funds for Promoting Science and Technology from the Science and Technology Agency, Japan; by a Grant-in-Aid for Scientific Research (B) (03454153) from the Ministry of Education, Science, and Culture of Japan; and grants from the Brain Science Foundation and Sankyo Co., Ltd.

## REFERENCES

1. Waite, M. (1987) *The Phospholipases*, pp.111-113, Plenum Publishing Corp. New York
2. Sammuelson, B., Goldyne, M., Branstrom, E., Hamberg, M., Hammarstrom, S., and Malmsten, C. (1978) *Ann. Rev. Biochem.* 47, 997-1029
3. Bazan, N. G. (1976) *Function and Metabolism of Phospholipids in Central and Peripheral Nervous System*, pp.317-335, Plenum Publishing Corp. New York
4. Wolfe, L. S., and Cocceani, F. (1979) *Ann. Rev. Physiol.* 41, 669-684
5. Shimizu, T., and Wolfe, L. S. (1990) *J. Neurochem.* 55, 1-15
6. Hayashi, O (1991) *FASEB J.* 5, 2575-2581
7. Yoshihara, Y., and Watanabe, Y. (1990) *Biochem. Biophys. Res. Commun.* 170, 484-490

8. Clark, J. D., Lin, L. -L., Kriz, R. W., Ramesha, C. S., Sultzman, L. A., Lin, A. Y., Milona, N., and Knopf, J. L. (1991) *Cell* 65, 1043-1051
9. Sharp, J. D., White, D. L., Chiou, W. X., Goodson, T., Gamboa, G. C., McClure, D., Burgett, S., Hoskins, A., Skatrud, P. L., Sportsman, J. R., Becker, G. W., Kang, L. H., Roberts, E. F., and Krammer, R. M. (1991) *J. Biol. Chem.* 266, 14850-14853
10. Teramoto, T., Tojo, H., Yamano, T., and Okamoto, M. (1983) *J. Biochem. (Tokyo)* 93, 1353-1360
11. Jacobson, M. (1991) *Developmental Neurobiology* (3rd ed.) Plenum Publishing Corp. New York
12. McConnell, S. K., Ghosh, A., and Shatz, C. J. (1989) *Science* 245, 978-982
13. Negre-Aminou, P., and Phенninger, K. H. (1991) *J. Cell. Biol.* 115, 102a